Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Travoprost.

John Waugh1, Blair Jarvis

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|August 1, 2002
PubMed
Summary
This summary is machine-generated.

Travoprost eye drops effectively lower intraocular pressure (IOP) in glaucoma patients. This prostaglandin analogue demonstrates superior efficacy compared to placebo and timolol, with comparable results to latanoprost.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nasal high flow therapy for bronchiolitis.

Journal of paediatrics and child health·2024
Same author

Performance of artificial intelligence in 7533 consecutive prevalent screening mammograms from the BreastScreen Australia program.

European radiology·2023
Same author

Effect of Early High-Flow Nasal Oxygen vs Standard Oxygen Therapy on Length of Hospital Stay in Hospitalized Children With Acute Hypoxemic Respiratory Failure: The PARIS-2 Randomized Clinical Trial.

JAMA·2023
Same author

Cost-Effectiveness of Care Coordination for Children With Chronic Noncomplex Medical Conditions: Results From a Multicenter Randomized Clinical Trial.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2022
Same author

Hospital presentations with diabetic ketoacidosis: A retrospective review.

Australasian emergency care·2022
Same author

The effect of different service models on quality of care in the assessment of autism spectrum disorder in children: study protocol for a multi-centre randomised controlled trial.

BMC pediatrics·2022
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Glaucoma and ocular hypertension are common conditions characterized by elevated intraocular pressure (IOP).
  • Prostaglandin analogues are a key therapeutic class for managing elevated IOP.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of travoprost 0.004% in reducing intraocular pressure.
  • To compare travoprost with placebo, timolol, and latanoprost in patients with open-angle glaucoma or ocular hypertension.

Main Methods:

  • Randomised, double-blind studies were conducted.
  • Efficacy was assessed by measuring intraocular pressure reduction.
  • Adjunctive therapy with timolol was also investigated.

Main Results:

  • Travoprost 0.004% significantly reduced IOP compared to placebo and timolol 0.5%.

Related Experiment Videos

  • Efficacy was comparable to latanoprost 0.005%.
  • Adjunctive travoprost showed significant additional IOP reduction when combined with timolol.

    • Conclusions:

    • Travoprost 0.004% is a highly effective treatment for lowering IOP in glaucoma and ocular hypertension.
    • The drug is well-tolerated, with mild and transient adverse events like ocular hyperaemia.